Albemarle Corporation (AMC)
XETRA Stock Exchange · Germany · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 85.74 |
|---|---|
| 52-week range | 76.37 – 184.90 |
| Return, 1 month / 3 months | −11.1% / −18.2% |
| Return, 1 year / 3 years | +4.3% / −30.9% |
| Trend | Below its 200-day average |
| RSI (14) | 32 |
| Volatility (1 year) | 54.2% |
| Worst drawdown (1 year) | -52.9% |
| Average daily value traded | 0.17M EUR |
| Dividend yield | 1.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Albemarle Corporation is a specialty chemicals company based in the United States. It produces lithium compounds used in batteries and other applications, bromine-based specialty chemicals, and catalysts for refining and petrochemical processes. Its customers include battery makers, chemical manufacturers, refiners and industrial firms around the world. The company supplies materials for energy storage, flame retardants, and process technologies through its several business segments.
On this site Albemarle Corporation appears as a stock on the XETRA Stock Exchange (Germany), code AMC, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Albemarle Corporation (AMC) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 85.74 on 19 October 2026.
Its price-based Market X-Ray is 28 out of 100 (a weak price profile), ranking 591 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 4.3% and over the last three months it fell 18.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 8 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -34.6% | ||
| From 52-week high | -52.9% | ||
| Momentum | 30 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -18.2% | ||
| 6-month return | -47.3% | ||
| 12-month return, skipping the last month | 17.4% | ||
| Risk (lower is better) | 18 · Weak | Volatile, with deep drawdowns. | |
| Volatility (1 year) | 54.2% | ||
| Worst drawdown (1 year) | -52.9% | ||
| Liquidity | 51 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.17M EUR | ||
| Zero-volume days | 1.7% | ||
| Income | 60 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.7% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Risk (lower is better): Volatile, with deep drawdowns.
Returns
| 1 week | −2.4% |
|---|---|
| 1 month | −11.1% |
| 3 months | −18.2% |
| 6 months | −47.3% |
| 1 year | +4.3% |
| 3 years | −30.9% |
| 5 years | −62.1% |
Signals
| 50-day / 200-day average | 103.35 / 131.11 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.85 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 Sep 2026 | USD 0.3647 |
| 12 Jun 2026 | USD 0.3603 |
| 13 Mar 2026 | USD 0.3603 |
| 12 Dec 2025 | USD 0.3603 |
| 12 Sep 2025 | USD 0.3603 |
| 13 Jun 2025 | USD 0.3603 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.